Dendreon Overstated Demand For Provenge: Investors

Law360, New York (September 20, 2011, 4:22 PM EDT) -- Dendreon Corp. was hit with a shareholder class action in Washington federal court Monday that accuses executives of the Seattle-based biotechnology company of misleading investors about demand for its prostate cancer drug Provenge.

Shareholder Michael Wendt claims that the false statements artificially inflated Dendreon's stock price, a violation of the Securities Exchange Act. Wendt also accuses Dendreon officers and directors of defrauding investors by trading on the false information.

Wendt seeks to establish a class of investors that purchased Dendreon stock between April 29, 2010, when...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Wendt v. Dendreon Corporation et al


Case Number

2:11-cv-01568

Court

Washington Western

Nature of Suit

Securities/Commodities

Judge

James L. Robart

Date Filed

September 20, 2011

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.